Cases

Search for a case

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Cases

February 5, 2024

Everbridge, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Everbridge, Inc. (“Everbridge” or the “Company”)(NASDAQ: EVBG), in connection with its acquisition by Thoma Bravo. Under the merger agreement, the Company’s shareholders will receive $28.60 per share. The transaction is valued at approximately $1.5 billion.

Join Case →

February 5, 2024

Haynes International, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Haynes International, Inc. (“Haynes” or the “Company”) (NASDAQ: HAYN), in connection with its acquisition by North American Stainless. Under the merger agreement, the Company’s shareholders will receive $61.00 per share. The transaction is valued at approximately $970 million.

Join Case →

February 5, 2024

Catalent, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), in connection with its acquisition by Novo Holdings. Under the merger agreement, the Company’s shareholders will receive $63.50 per share. The transaction is valued at approximately $16.5 billion.

Join Case →

January 23, 2024

Inhibrx, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Inhibrx, Inc. (“Inhibrx” or the “Company”)(NASDAQ: INBX), in connection with its acquisition by Aventis Inc. Under the merger agreement, the Company’s shareholders will receive: (i) $30.00 per share; (ii) one contingent value right (“CVR”) per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone; and (iii) one SEC-registered, publicly listed, share of New Inhibrx per every four shares of Inhibrx common stock held.

Join Case →

January 16, 2024

Carrols Restaurant Group, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (NASDAQ: TAST), in connection with its acquisition by Restaurant Brands International Inc. (NYSE: QSR). Under the merger agreement, the Company’s shareholders will receive $9.55 per share. The transaction is valued at approximately $1.0 billion.

Join Case →

January 10, 2024

Juniper Networks, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Juniper Networks, Inc. (“Juniper” or the “Company”) (NYSE: JNPR), in connection with its acquisition by Hewlett Packard Enterprise Company (NYSE: HPE). Under the merger agreement, the Company’s shareholders will receive $40.00 per share. The transaction is valued at approximately $14 billion.

Join Case →

January 8, 2024

Ambrx Biopharma Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Ambrx Biopharma Inc. (“Ambrx” or the “Company”) (NASDAQ: AMAM) in connection with its acquisition by Johnson & Johnson (NYSE: JNJ). Under the merger agreement, the Company’s shareholders will receive $28.00 per share. The transaction is valued at approximately $2.0 billion.

Join Case →

January 8, 2024

Harpoon Therapeutics, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Harpoon Therapeutics, Inc. (“Harpoon” or the “Company”) (NASDAQ: HARP), in connection with its acquisition by a subsidiary of Merck & Co., Inc. (NYSE: MRK). Under the merger agreement, the Company’s shareholders will receive $23.00 per share. The transaction is valued at approximately $680 million.

Join Case →

January 8, 2024

Axonics, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Axonics, Inc. (“Axonics” or the “Company”) (NASDAQ: AXNX), in connection with its acquisition by Boston Scientific Corporation (NYSE: BSX). Under the merger agreement, the Company’s shareholders will receive $71.00 per share. The transaction is valued at approximately $3.4 billion.

Join Case →

We will fight for you and have your back no matter what. Join the tens of thousands of people we’ve helped.

Cases

Search for a case

Cases

Everbridge, Inc. Investigation

Haynes International, Inc. Investigation

Catalent, Inc. Investigation

Inhibrx, Inc. Investigation

Carrols Restaurant Group, Inc. Investigation

Juniper Networks, Inc. Investigation

Ambrx Biopharma Inc. Investigation

Harpoon Therapeutics, Inc. Investigation

Axonics, Inc. Investigation

Where to find us?

new york

california

georgia

NEW JERSEY